Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas

Conditions:   Neuroendocrine Tumors;   Neuroendocrine Carcinoma;   Neuroendocrine Cancer Intervention:   Drug: Pembrolizumab Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp. Not yet recruiting - verified September 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials